Status:
COMPLETED
5-Cog Battery for Detecting Cognitive Impairment and Dementia
Lead Sponsor:
Albert Einstein College of Medicine
Collaborating Sponsors:
National Institute of Neurological Disorders and Stroke (NINDS)
Conditions:
Dementia
Cognitive Impairment
Eligibility:
All Genders
65+ years
Phase:
NA
Brief Summary
Despite the availability of numerous cognitive assessment tools, cognitive impairment related to dementia is frequently under-diagnosed in primary care settings. The investigators have developed a 5-m...
Detailed Description
Despite the availability of numerous cognitive assessment tools, cognitive impairment related to dementia is frequently under-diagnosed in primary care settings, and is a more prevalent problem among ...
Eligibility Criteria
Inclusion
- Age 65 and older.
- Presence of cognitive or memory concerns expressed by patient, caregiver, health care provider or other source who knows the patient.
- Registered as patient at Montefiore Medical Center and have a primary care doctor appointment that day.
- Able to hear and see well enough to complete intervention or control assessments.
- English or Spanish speaking.
Exclusion
- Prior diagnosis of dementia or MCI as ascertained by ICD-10 codes or the documentation of prescription for anti-dementia medications in EMR. Patients with a diagnosis containing any of the following terms will be excluded:
- "Dementia"
- "Mild Cognitive Impairment"
- "Alzheimer's Disease"
- "Creutzfeldt-Jakob Disease"
- "Major Neurocognitive Disorder"
- "Minor Neurocognitive Disorder"
- Patients with any of the following medications documented in their EMR will be excluded (generic = brand):
- Donepezil = Aricept
- Memantine = Namenda
- Rivastigmine = Exelon
- Galantamine = Razadyne
- Donepezil and Memantine = Namzaric
- Adults who are permanent residents of a nursing facility.
- Patients who do not speak English or Spanish.
- Patients who are not seeing a primary care physician at the clinic that day.
- Patients who are blind or deaf or cannot hear loud voice even with hearing aids.
Key Trial Info
Start Date :
May 28 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 15 2023
Estimated Enrollment :
1201 Patients enrolled
Trial Details
Trial ID
NCT03816644
Start Date
May 28 2019
End Date
March 15 2023
Last Update
January 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Albert Einstein College of Medicine
The Bronx, New York, United States, 10461